COMMUNIQUÉS West-GlobeNewswire

Equillium Granted U.S. FDA Orphan Drug Designations for EQ001 (itolizumab) for both the Prevention and Treatment of Acute Graft-Versus-Host Disease
07/02/2019
LA JOLLA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the U.S. Food and Drug [...]
Momenta Pharmaceuticals Announces Oral Presentation of New Data for M281 at the Society for Maternal-Fetal Medicine 2019 Annual Meeting
07/02/2019
Study highlights ability of M281 to inhibit transfer of immunoglobulin G from maternal to fetal circulation in ex vivo placental perfusion model M281 currently being evaluated in an international Phase 2 study in [...]
Evelo Biosciences to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 14, 2019
07/02/2019
CAMBRIDGE, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic [...]
Forty Seven Inc. to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day
07/02/2019
MENLO PARK, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today [...]
Replimune to Present at Two Upcoming Investor Conferences
07/02/2019
WOBURN, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced that Robert Coffin [...]
Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
07/02/2019
PHILADELPHIA and OXFORD, United Kingdom, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Fourth Quarter [...]
Sport Endurance Signs Letter of Intent to Acquire CBD Animal Health and Wellness Company, Bona Vida
07/02/2019
BROOKLYN, N.Y., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Sport Endurance, Inc. (OTCQB: SENZ) (the “Company”), to be reincorporated as Better Choice Company, Inc., today announced that it has signed a Letter of Intent (“LOI”) [...]
CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™ Provided Intravenously for Patients with Niemann-Pick Disease Type C
07/02/2019
ALACHUA, Fla., Feb. 07, 2019 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, [...]
Arch Biopartners Awarded NRC-IRAP Funding to Further Develop Metablok Drug Program
07/02/2019
TORONTO, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that the National Research Council – Industrial Research Assistance [...]
VBI Vaccines Announces Third Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent GBM Patients
07/02/2019
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the study without modification Enrollment is complete in the high-dose study arm of Part A Expanded immunologic data and 6-month [...]
InspireMD to Report Fourth Quarter and Fiscal 2018 Financial Results and Provide Business Update on Tuesday, February 19
07/02/2019
Conference Call Scheduled for 8am Eastern Time TEL AVIV, Israel, Feb. 07, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of [...]
Avadel Pharmaceuticals Announces Restructuring to Focus on FT218 Clinical Development Program
07/02/2019
- Company cost structure expected to be reduced by $70 to $75 million in 2019 – - Approximately $100 million in cash and marketable securities at December 31, 2018 – DUBLIN, Ireland, Feb. 07, 2019 (GLOBE NEWSWIRE) -- [...]
Shockwave Appoints Laura Francis to Board of Directors
07/02/2019
SANTA CLARA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Shockwave Medical, a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, today [...]
Agile Therapeutics to Present at the 2019 BIO CEO and Investor Conference
07/02/2019
PRINCETON, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the [...]
Clinical update: Dovitinib DRP data mining successfully completed and new LiPlaCis data continues to support an FDA breakthrough designation strategy
07/02/2019
Press release Hoersholm, Denmark and Cambridge, MA, US, February 7, 2019 – Oncology Venture A/S (“OV” or “the Company”) today provides a clinical update on its precision drug projects. Oncology Venture has finalized the [...]
ICU Medical, Inc. Announces Time of Fourth Quarter and Fiscal Year 2018 Earnings Conference Call
07/02/2019
SAN CLEMENTE, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care [...]
Moleculin Announces Approval for Third Drug to Commence Clinical Trials
07/02/2019
MBRX will now have three distinctive oncology drugs in clinic in four ongoing clinical trials WP1220, a STAT3 inhibitor, to begin clinical trials in Poland for the treatment of Cutaneous T-Cell Lymphona (“CTCL”), a rare [...]
Meridian Launches New Range of Lyo-Ready PCR Mixes
07/02/2019
CINCINNATI, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that following the successful release of the Lyo-Ready qPCR Mix, Meridian is proud to introduce its next-generation [...]
Tabula Rasa HealthCare Announces Proposed $250 Million Offering of Convertible Notes
07/02/2019
MOORESTOWN, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) (“TRHC”) today announced its intention to offer, subject to market and other conditions, $250 million principal amount of [...]

Pages